IBDEI1LZ ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,26917,2)
 ;;=^184182
 ;;^UTILITY(U,$J,358.3,26918,0)
 ;;=I82.891^^132^1307^14
 ;;^UTILITY(U,$J,358.3,26918,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26918,1,3,0)
 ;;=3^Embolism/Thrombosis Oth Spec Veins,Chronic
 ;;^UTILITY(U,$J,358.3,26918,1,4,0)
 ;;=4^I82.891
 ;;^UTILITY(U,$J,358.3,26918,2)
 ;;=^5007939
 ;;^UTILITY(U,$J,358.3,26919,0)
 ;;=I82.890^^132^1307^13
 ;;^UTILITY(U,$J,358.3,26919,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26919,1,3,0)
 ;;=3^Embolism/Thrombosis Oth Spec Veins,Acute
 ;;^UTILITY(U,$J,358.3,26919,1,4,0)
 ;;=4^I82.890
 ;;^UTILITY(U,$J,358.3,26919,2)
 ;;=^5007938
 ;;^UTILITY(U,$J,358.3,26920,0)
 ;;=E78.0^^132^1308^12
 ;;^UTILITY(U,$J,358.3,26920,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26920,1,3,0)
 ;;=3^Pure Hypercholesterolemia
 ;;^UTILITY(U,$J,358.3,26920,1,4,0)
 ;;=4^E78.0
 ;;^UTILITY(U,$J,358.3,26920,2)
 ;;=^5002966
 ;;^UTILITY(U,$J,358.3,26921,0)
 ;;=E78.1^^132^1308^13
 ;;^UTILITY(U,$J,358.3,26921,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26921,1,3,0)
 ;;=3^Pure Hyperglyceridemia
 ;;^UTILITY(U,$J,358.3,26921,1,4,0)
 ;;=4^E78.1
 ;;^UTILITY(U,$J,358.3,26921,2)
 ;;=^101303
 ;;^UTILITY(U,$J,358.3,26922,0)
 ;;=E78.2^^132^1308^11
 ;;^UTILITY(U,$J,358.3,26922,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26922,1,3,0)
 ;;=3^Mixed Hyperlipidemia
 ;;^UTILITY(U,$J,358.3,26922,1,4,0)
 ;;=4^E78.2
 ;;^UTILITY(U,$J,358.3,26922,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,26923,0)
 ;;=I10.^^132^1308^3
 ;;^UTILITY(U,$J,358.3,26923,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26923,1,3,0)
 ;;=3^Essential Primary Hypertension
 ;;^UTILITY(U,$J,358.3,26923,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,26923,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,26924,0)
 ;;=I11.9^^132^1308^10
 ;;^UTILITY(U,$J,358.3,26924,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26924,1,3,0)
 ;;=3^Hypertensive Heart Disease w/o Heart Failure
 ;;^UTILITY(U,$J,358.3,26924,1,4,0)
 ;;=4^I11.9
 ;;^UTILITY(U,$J,358.3,26924,2)
 ;;=^5007064
 ;;^UTILITY(U,$J,358.3,26925,0)
 ;;=I11.0^^132^1308^9
 ;;^UTILITY(U,$J,358.3,26925,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26925,1,3,0)
 ;;=3^Hypertensive Heart Disease w/ Heart Failure
 ;;^UTILITY(U,$J,358.3,26925,1,4,0)
 ;;=4^I11.0
 ;;^UTILITY(U,$J,358.3,26925,2)
 ;;=^5007063
 ;;^UTILITY(U,$J,358.3,26926,0)
 ;;=I12.0^^132^1308^8
 ;;^UTILITY(U,$J,358.3,26926,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26926,1,3,0)
 ;;=3^Hypertensive Chr Kidney Disease w/ ESRD
 ;;^UTILITY(U,$J,358.3,26926,1,4,0)
 ;;=4^I12.0
 ;;^UTILITY(U,$J,358.3,26926,2)
 ;;=^5007065
 ;;^UTILITY(U,$J,358.3,26927,0)
 ;;=I13.10^^132^1308^6
 ;;^UTILITY(U,$J,358.3,26927,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26927,1,3,0)
 ;;=3^HTN Hrt & Chr Kdny Dis w/o Hrt Fail w/ Stg 1-4 Chr Kdny
 ;;^UTILITY(U,$J,358.3,26927,1,4,0)
 ;;=4^I13.10
 ;;^UTILITY(U,$J,358.3,26927,2)
 ;;=^5007068
 ;;^UTILITY(U,$J,358.3,26928,0)
 ;;=I13.0^^132^1308^4
 ;;^UTILITY(U,$J,358.3,26928,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26928,1,3,0)
 ;;=3^HTN Hrt & Chr Kdny Dis w/ Hrt Fail w/ Stg 1-4 Chr Kdny
 ;;^UTILITY(U,$J,358.3,26928,1,4,0)
 ;;=4^I13.0
 ;;^UTILITY(U,$J,358.3,26928,2)
 ;;=^5007067
 ;;^UTILITY(U,$J,358.3,26929,0)
 ;;=I13.11^^132^1308^7
 ;;^UTILITY(U,$J,358.3,26929,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26929,1,3,0)
 ;;=3^HTN Hrt & Chr Kdny Dis w/o Hrt Fail w/ Stg 5 Chr Kdny
 ;;^UTILITY(U,$J,358.3,26929,1,4,0)
 ;;=4^I13.11
 ;;^UTILITY(U,$J,358.3,26929,2)
 ;;=^5007069
 ;;^UTILITY(U,$J,358.3,26930,0)
 ;;=I13.2^^132^1308^5
 ;;^UTILITY(U,$J,358.3,26930,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26930,1,3,0)
 ;;=3^HTN Hrt & Chr Kdny Dis w/ Hrt Fail w/ Stg 5 Chr Kdny
